Journal article

Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia

BD Hock, LJ Fernyhough, SM Gough, A Steinkasserer, AG Cox, JL McKenzie

Leukemia Research | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2009

Abstract

Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter (P = 0.038) treatment free survival. Culture of CLL cells with solid phase CD83 mAb + IL-4 significantly increases sCD83 release (23-117-fold, P = 0.013) and ligation of normal donor PBMC with solid phase CD83 mAb alone induces similar significant increases in sCD83 release (P = 0.003). RT-PCR analysis detected the presence of a transcript for sCD83 in 2/3 CLL samples. These results suggest sCD83 release may play a regulatory role in CLL progression. © 2009 Elsevier Lt..

View full abstract

University of Melbourne Researchers